WM

Six Strengths of WM Motor that Attracted Kaixin Auto Holdings to the Proposed Acquisition

Retrieved on: 
Wednesday, September 20, 2023
EV, ASEAN, Kaixin001, OTA, Julius Caesar, HMI, WM, Silicon carbide, Acquisition, Ajax, Motion, SUV, European, City, BMS, MOSFET, Warehouse

BEIJING, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Kaixin Auto Holdings ("Kaixin" or the "Company") (NASDAQ: KXIN) today announced that it had identified several noteworthy strengths in WM Motor Holdings Limited ("WM Motor") that attracted the Company to the proposed acquisition.

Key Points: 
  • BEIJING, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Kaixin Auto Holdings ("Kaixin" or the "Company") (NASDAQ: KXIN) today announced that it had identified several noteworthy strengths in WM Motor Holdings Limited ("WM Motor") that attracted the Company to the proposed acquisition.
  • On September 11, Kaixin announced the non-binding acquisition term sheet with WM Motor to acquire 100% of equity of WM Motor.
  • As a pioneer in bringing innovative smart EV technologies to China’s mainstream auto market, WM Motor possesses six unique strengths.
  • WM Motor has built a comprehensive SUV+ Sedan smart EV portfolio, including three SUVs (EX5/EX6/W6) and two sedans (E5 including E5 Pro/M7).

Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia

Retrieved on: 
Monday, September 18, 2023
DLBCL, European Medicines Agency, NDA, Cancer, PRIME, B-cell lymphoma, WM, EMA, PDC, Patient, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, EU

The PRIME program aims to optimize development plans and speed up evaluation of medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options.

Key Points: 
  • The PRIME program aims to optimize development plans and speed up evaluation of medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options.
  • These medicines are considered priority medicines by the EMA and are intended to reach patients earlier.
  • To be accepted for PRIME, new therapies must demonstrate the potential to significantly address an unmet medical need in clinical trials.
  • “PRIME designation from the EMA further underscores our confidence in iopofosine I 131 to provide a differentiated and highly needed new treatment option for patients with WM,” said James Caruso, president and CEO of Cellectar.

Debrand Services Opens New Headquarters in Surrey, Canada

Retrieved on: 
Thursday, September 14, 2023
ACT, Irritant, Hope, CCTC, Recycling, Aircraft, USC, WM, Kit, Textile, ACP, Fine chemical, Warehouse, Disassembler, Debranding

VANCOUVER, BC, Sept. 14, 2023 /PRNewswire-PRWeb/ -- Debrand, a Vancouver-based reverse logistics solutions provider, today announced the opening of its new headquarters in Surrey, BC to provide state-of-the-art textile sortation services as demand for the company's industry-leading innovations continues to grow. The new 21,000-square-foot facility is the first of its kind in Canada, and just one of a few in North America providing advanced sortation technology for textile reuse, recycling, and recovery.

Key Points: 
  • Debrand, a Vancouver-based reverse logistics solutions provider, today announced the opening of its new headquarters in Surrey, BC to provide state-of-the-art textile sortation services as demand for the company's industry-leading innovations continues to grow.
  • VANCOUVER, BC, Sept. 14, 2023 /PRNewswire-PRWeb/ -- Debrand , a Vancouver-based reverse logistics solutions provider, today announced the opening of its new headquarters in Surrey, BC to provide state-of-the-art textile sortation services as demand for the company's industry-leading innovations continues to grow.
  • The new 21,000-square-foot facility is the first of its kind in Canada, and just one of a few in North America providing advanced sortation technology for textile reuse, recycling, and recovery.
  • With a reputation for exceptional service and tech-enabled solutions, Debrand specializes in reverse logistics for the apparel and footwear industry.

SOHM, Inc. Announces the Appointment of Wm. Dewey Rushing as VP of Quality with Immediate Effect

Retrieved on: 
Monday, September 11, 2023
IBN, Pharmaceutical Advertising Advisory Board, Master of Science in Quality Management and Analytics, Kansas State University, Advisory board, CGMP, OTC, Biology, FDA, IND, Microbiology, San Diego State University, Pharmaceutical industry, Science, WM, Quality

Dewey Rushing as a Vice President-Quality with the company.

Key Points: 
  • Dewey Rushing as a Vice President-Quality with the company.
  • Dewey Rushing is a senior compliance remediation and quality professional with more than 30 years of experience in quality assurance and cGMP compliance for FDA-regulated products.
  • SOHM has appointed him as the Vice President of Quality, recognizing his exceptional qualifications and experience in pharmaceutical quality validation and cGMP compliance."
  • Mr. Rushing is a well-known expert in the field of pharmaceutical quality validation and cGMP compliance and has worked with several leading companies in the industry.

Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing

Retrieved on: 
Monday, September 11, 2023
Second line, Common stock, ADAR1, DLBCL, New Drug Application, Disclosure, NDA, Cancer, Regulation D, Exchange, Sale, B-cell lymphoma, WM, Waldenström, Securities and Exchange Commission (Philippines), PDC, Patient, Oppenheimer, Security (finance), FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, AUGC Deportiva Ceuta, Pharmaceutical industry, Series

The financing was led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors.

Key Points: 
  • The financing was led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors.
  • Conversion of the Series E Preferred Stock into shares of common stock of the Company is subject to approval by the Company's stockholders.
  • Oppenheimer & Co. Inc. acted as the sole placement agent for the private placement.
  • Cellectar has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock underlying the Series E Preferred Stock.

Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

Retrieved on: 
Tuesday, September 5, 2023
Second line, Common stock, ADAR1, DLBCL, PIPE, New Drug Application, Disclosure, Cancer, Regulation D, Exchange, Sale, B-cell lymphoma, WM, Waldenström, Securities and Exchange Commission (Philippines), PDC, Patient, Oppenheimer, Security (finance), FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, AUGC Deportiva Ceuta, Series

FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced it has entered into a securities purchase agreement with certain institutional investors for a private placement financing (the “PIPE”) that is expected to result in gross proceeds of up to $102.9 million, including an initial funding of $24.5 million priced at the company’s common stock closing price on September 1, 2023 of $1.82 per share. The financing is being led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors.

Key Points: 
  • The financing is being led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors.
  • “This financing with current and new investor funds of up to $102.9 million reflects the significant value of our lead asset iopofosine and R&D pipeline,” said James Caruso, president and CEO of Cellectar.
  • “With the initial $24.5 million, we are able to fully fund all corporate activities through the completion of our pivotal trial and expected reporting of top-line data later this year.
  • Oppenheimer & Co. Inc. acted as the sole placement agent for the private placement.

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Retrieved on: 
Wednesday, August 16, 2023
Lymphoma, International Workshop on Lung Health, Waldenström macroglobulinemia, US Foods, University, CD19, Chronic lymphocytic leukemia, Follicular lymphoma, CRS, Fred Hutchinson Cancer Research Center, University of Washington, Clinical trial, Immunoglobulin M, Bone marrow, NHL, PET-CT, Immunotherapy, Associate, Translation, Regenerative medicine, WM, Patient, Cancer, CR, Orphan, Diagnosis, Trial of the century, Hairy cell leukemia, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mustang, DSM-IV codes, Food, Safety, Disease, Grade 2, Medical imaging, Vaccine, Pharmaceutical industry

WORCESTER, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia (“CLL”), demonstrating clinical responses as well as safety and efficacy consistent with the ongoing Phase 1/2 clinical trial taking place at Fred Hutchinson Cancer Center (“Fred Hutch”).

Key Points: 
  • The multicenter data also show persistence of CAR-T cells at 6+ months and favorable safety data with only Grade 1 cytokine release syndrome (“CRS”) reported to date.
  • Additionally, the data from the ongoing clinical trial at Fred Hutch continue to demonstrate a high rate of complete and durable responses.”
    Dr. Shadman also presented data from the ongoing Fred Hutch Phase 1/2 clinical trial, specific to two B-NHL cohorts, follicular lymphoma (“FL”) and WM.
  • Furthermore, Mustang anticipates requesting regenerative medicine advanced therapy (RMAT) designation for WM from the FDA in 2024.
  • Finally, data from the Fred Hutch clinical trial also support the potential of MB-106 to be administered as outpatient therapy and provide a best-in-class immunotherapy option for patients treated previously with CD19-directed CAR-T cell therapy.

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, August 14, 2023
Waldenström macroglobulinemia, Partnership, Mayo Clinic, Arm, CD19, Chronic lymphocytic leukemia, Follicular lymphoma, CRS, Fred Hutchinson Cancer Research Center, CD20, European Hematology Association, Clinical trial, Lymphoma, Research, History, Translation, WM, CAR, Waldenström, Acquisition, International Conference on Afghanistan, London (2010), Cytokine release syndrome, Patient, Cancer, CR, Clinical professor, Immunoglobulin M, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mustang, Conference, ORR, DSM-IV codes, Food, Safety, Disease, Pharmaceutical industry, Cryptocurrency, Video game

WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.

Key Points: 
  • WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.
  • Research and development expenses were $10.8 million for the second quarter of 2023, compared to $15.2 million for the second quarter of 2022.
  • Non-cash, stock-based expenses included in research and development were $(0.1) million for the second quarter of 2023, compared to $0.4 million for the second quarter of 2022.
  • General and administrative expenses were $3.1 million for the second quarter of 2023, compared to $3.1 million for the second quarter of 2022.

China Automotive Fragrance and Air Purification Systems Research Report 2023: Driving Wellness Innovations - Exploring the Integration of Fragrance and Air Purification - ResearchAndMarkets.com

Retrieved on: 
Friday, August 18, 2023
Automotive Manufacturing, Manufacturing, Vehicle Technology, Other Automotive, Automotive, GLE, IAPS, Valeo, International, Mercedes-Benz, S class, Filter (signal processing), Geely, Original equipment manufacturer, Symrise, IVI, AMG, CLS, AQS, NIO, Noetics, Toyota, Certification, WM, HVAC, NFC, Plasma, Denso, WeChat, BMW, UV, AIO, XPeng G9, GLS, Highlander, Architecture, Growth, HEPA, Filtration, OEM, Palladium, Rail transport, Heating, ventilation, and air conditioning, Perfume, Civil engineering, Givaudan, Venza

The "China Automotive Fragrance and Air Purification Systems Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Automotive Fragrance and Air Purification Systems Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • From 2020 to 2023, the installations of automotive air purification and fragrance systems will sustain steady growth.
  • It is predicted that in 2023 the installations of automotive air purification systems will exceed 6 million units, and that of fragrance systems will reach 1.03 million units.
  • 1.2.2 Principle of Air Purification System: Sources of Pollution and Conventional Purification Process
    1.2.4 Major Air Purification Technologies:

The Abbi Agency Wins Two Accolades at the 2023 Bulldog PR Awards

Retrieved on: 
Monday, August 14, 2023
Communication, Public Relations Society of America, PRSA, Seafood, Recycling, Creativity, WM, Skin, Bulldog

RENO, Nev., Aug. 14, 2023 /PRNewswire-PRWeb/ -- The Abbi Agency, a leading woman-owned, operated and Nevada-based performance marketing agency, won two awards at the 2023 Bulldog PR Awards, including Best Brand Launch for Morro Bay and Best Hyperlocal Campaign for WM.

Key Points: 
  • RENO, Nev., Aug. 14, 2023 /PRNewswire-PRWeb/ -- The Abbi Agency , a leading woman-owned, operated and Nevada-based performance marketing agency, won two awards at the 2023 Bulldog PR Awards, including Best Brand Launch for Morro Bay and Best Hyperlocal Campaign for WM.
  • The Bulldog PR Awards, which recognize the best and brightest in corporate communications and public relations, have further cemented The Abbi Agency as a continued trailblazer in its industry.
  • "We are immensely proud to receive these awards," said Abbi Whitaker, Founder and President of The Abbi Agency.
  • To learn more about the 2023 Bulldog PR Awards, subscribe to their newsletter .